Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.50 |
| ▸ | REN | P00797 | 3/20 | 0.49 |
| ▸ | GRB2 | P62993 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29129167 | 0.95 | PTPN1 (0.51) | PTPN1RENGRB2TLR2TLR1 | |
| SCHEMBL29129170 | 0.95 | PTPN1 (0.51) | PTPN1RENGRB2TLR2TLR1 | |
| SCHEMBL8259207 | 0.91 | PAX8 (0.50) | PTPN1TLR2TLR1KMT2A | |
| SCHEMBL29613492 | 0.90 | TLR2 (0.47) | PTPN1GRB2TLR2TLR1KMT2A | |
| SCHEMBL29613495 | 0.90 | TLR2 (0.47) | PTPN1GRB2TLR2TLR1KMT2A | |
| SCHEMBL30565199 | 0.89 | TLR2 (0.47) | PTPN1TLR2TLR1KMT2A | |
| SCHEMBL13289729 | 0.88 | TLR2 (0.48) | PTPN1GRB2TLR2TLR1KMT2A | |
| SCHEMBL29613441 | 0.88 | NPY4R (0.53) | PTPN1KMT2A | |
| SCHEMBL29129044 | 0.87 | KMT2A (0.49) | PTPN1GRB2TLR2TLR1KMT2A | |
| SCHEMBL12340097 | 0.87 | KMT2A (0.48) | PTPN1TLR2TLR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | MTPN, DMPK, MBNL1 | PTPN1 4799/4885REN 4809/4885GRB2 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.